{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:00:00Z","timestamp":1780405200718,"version":"3.54.1"},"reference-count":60,"publisher":"The Endocrine Society","issue":"10","funder":[{"DOI":"10.13039\/100000062","name":"Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["ZIA DK043006"],"award-info":[{"award-number":["ZIA DK043006"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021671","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Approximately 50% to 70% of patients with multiple endocrine neoplasia type 1 (MEN1) die of duodenopancreatic neuroendocrine tumors (NETs). While c-MET inhibitors in combination with antivascular endothelial growth factor therapy have been shown to result in longer progression-free survival in patients with sporadic NETs, data regarding their efficacy in patients with MEN1-related NETs are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We sought to characterize c-MET expression in MEN1-related NETs and evaluate its association with clinicopathologic characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Forty-three tumors from 22 genetically confirmed patients with MEN1-related metastatic NETs were identified. Of these, 15 of 22 (68%) patients had distant metastases while the remaining 7 of 22 had locoregional metastases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>c-MET expression was assessed in these tumors via immunohistochemistry. A total of 19 of 43 (44%) were primary tumors (duodenum, pancreas, stomach) while the remaining were metastases. c-MET expression was scored as strongly positive in 3 of 43 (H-score &amp;gt;50), weakly positive in 6 of 43 (H-score: 10-50), and negative in 34 of 43 (H-score &amp;lt;10) tumors. All 3 tumors with strong positive c-MET expression were from patients with a distinctly aggressive clinical course. The 6 tumors with weakly positive c-MET expression were from patients with stable disease, including 4 with distant metastases. Of the 13 patients with all tumors negative for c-MET expression, all but 1 had stable disease. Age at initial NET diagnosis; tumor site, type or grade; number of sites of distant metastases; total number of surgeries for NETs; or the stability of overall tumor burden did not predict c-MET expression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings suggest a role for c-MET inhibition in personalizing therapy for patients with MEN1-related NETs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf147","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:33:20Z","timestamp":1757403200000},"source":"Crossref","is-referenced-by-count":2,"title":["MEN1-Related Neuroendocrine Tumors Show c-MET Overexpression"],"prefix":"10.1210","volume":"9","author":[{"given":"Raisa","family":"Ghosh","sequence":"first","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Akbulut","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7806-706X","authenticated-orcid":false,"given":"William F","family":"Simonds","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira M","family":"Sadowski","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E","family":"Blau","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita K","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-3340","authenticated-orcid":false,"given":"Smita","family":"Jha","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"2025092606115613600_bvaf147-B1","first-page":"288","article-title":"Pluriglandular syndrome. II. Multiple endocrine adenomas in man. A report of five cases and a review of literature","volume":"15","author":"Berdjis","year":"1962","journal-title":"Ophthalmologica"},{"issue":"2","key":"2025092606115613600_bvaf147-B2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/00365528509089663","article-title":"Frequency of endocrine disorders in patients with the Zollinger-Ellison syndrome","volume":"20","author":"Bardram","year":"1985","journal-title":"Scand J Gastroenterol"},{"issue":"5311","key":"2025092606115613600_bvaf147-B3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"issue":"7","key":"2025092606115613600_bvaf147-B4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/6.7.1177","article-title":"Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1","volume":"6","author":"Lemmens","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"9","key":"2025092606115613600_bvaf147-B5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/bjs\/znac006","article-title":"Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study","volume":"109","author":"Gaujoux","year":"2022","journal-title":"Br J Surg"},{"issue":"1","key":"2025092606115613600_bvaf147-B6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-020-02217-4","article-title":"Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience","volume":"68","author":"Oleinikov","year":"2020","journal-title":"Endocrine"},{"issue":"6","key":"2025092606115613600_bvaf147-B7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/jso.25667","article-title":"Prognostic factors and survival in MEN1 patients with gastrinomas: results from the DutchMEN study group (DMSG)","volume":"120","author":"van Beek","year":"2019","journal-title":"J Surg Oncol"},{"issue":"2","key":"2025092606115613600_bvaf147-B8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00268-009-0290-1","article-title":"Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients","volume":"34","author":"Goudet","year":"2010","journal-title":"World J Surg"},{"issue":"11","key":"2025092606115613600_bvaf147-B9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s002680010237","article-title":"Are patients with multiple endocrine neoplasia type I prone to premature death?","volume":"24","author":"Dean","year":"2000","journal-title":"World J Surg"},{"issue":"6","key":"2025092606115613600_bvaf147-B10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s002689900438","article-title":"Lethality of multiple endocrine neoplasia type I","volume":"22","author":"Doherty","year":"1998","journal-title":"World J Surg"},{"issue":"6","key":"2025092606115613600_bvaf147-B11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1530\/eje.0.1490577","article-title":"Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening?","volume":"149","author":"Geerdink","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025092606115613600_bvaf147-B12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","article-title":"Multiple endocrine neoplasia type 1: latest insights","volume":"42","author":"Brandi","year":"2020","journal-title":"Endocr Rev"},{"issue":"4","key":"2025092606115613600_bvaf147-B13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","article-title":"Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene","volume":"3","author":"Pennacchietti","year":"2003","journal-title":"Cancer Cell"},{"issue":"6940","key":"2025092606115613600_bvaf147-B14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/423593a","article-title":"Cancer: out of air is not out of action","volume":"423","author":"Bottaro","year":"2003","journal-title":"Nature"},{"issue":"2","key":"2025092606115613600_bvaf147-B15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jcp.21183","article-title":"The MET receptor tyrosine kinase in invasion and metastasis","volume":"213","author":"Benvenuti","year":"2007","journal-title":"J Cell Physiol"},{"issue":"12","key":"2025092606115613600_bvaf147-B16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"2025092606115613600_bvaf147-B17","doi-asserted-by":"crossref","first-page":"e13586","DOI":"10.1371\/journal.pone.0013586","article-title":"Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles","volume":"5","author":"Graveel","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"2025092606115613600_bvaf147-B18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7","article-title":"Expression of c-met is a strong independent prognostic factor in breast carcinoma","volume":"82","author":"Ghoussoub","year":"1998","journal-title":"Cancer"},{"issue":"10","key":"2025092606115613600_bvaf147-B19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcb.2009.07.002","article-title":"Crosstalk in Met receptor oncogenesis","volume":"19","author":"Lai","year":"2009","journal-title":"Trends Cell Biol"},{"issue":"4","key":"2025092606115613600_bvaf147-B20","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/0008-5472.CAN-06-1147","article-title":"c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion","volume":"67","author":"Sawada","year":"2007","journal-title":"Cancer Res"},{"issue":"31","key":"2025092606115613600_bvaf147-B21","doi-asserted-by":"crossref","first-page":"12903","DOI":"10.1073\/pnas.0810402106","article-title":"Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer","volume":"106","author":"Ponzo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2025092606115613600_bvaf147-B22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.20598","article-title":"C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2\/neu","volume":"113","author":"Lengyel","year":"2005","journal-title":"Int J Cancer"},{"issue":"1","key":"2025092606115613600_bvaf147-B23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/cncr.23972","article-title":"Prognostic significance of c-Met expression in glioblastomas","volume":"115","author":"Kong","year":"2009","journal-title":"Cancer"},{"issue":"18","key":"2025092606115613600_bvaf147-B24","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1038\/onc.2010.16","article-title":"Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells","volume":"29","author":"Xu","year":"2010","journal-title":"Oncogene"},{"issue":"16","key":"2025092606115613600_bvaf147-B25","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1073\/pnas.1600007113","article-title":"Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors","volume":"113","author":"Krampitz","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025092606115613600_bvaf147-B26","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1074\/jbc.M113.533612","article-title":"GSK-3beta protein phosphorylates and stabilizes HLXB9 protein in insulinoma cells to form a targetable mechanism of controlling insulinoma cell proliferation","volume":"289","author":"Desai","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"2025092606115613600_bvaf147-B27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/ERC-12-0077","article-title":"The embryonic transcription factor Hlxb9 is a menin interacting partner that controls pancreatic \u03b2-cell proliferation and the expression of insulin regulators","volume":"20","author":"Shi","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"42","key":"2025092606115613600_bvaf147-B28","doi-asserted-by":"crossref","first-page":"25595","DOI":"10.1074\/jbc.M115.661413","article-title":"Pro-oncogenic roles of HLXB9 protein in insulinoma cells through interaction with Nono protein and down-regulation of the c-Met inhibitor Cblb (Casitas B-lineage Lymphoma b)","volume":"290","author":"Desai","year":"2015","journal-title":"J Biol Chem"},{"issue":"2","key":"2025092606115613600_bvaf147-B29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1210\/en.2017-03155","article-title":"Functional defects from endocrine disease-associated mutations in HLXB9 and its interacting partner, NONO","volume":"159","author":"Kharade","year":"2018","journal-title":"Endocrinology"},{"issue":"2","key":"2025092606115613600_bvaf147-B30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1210\/me.2014-1304","article-title":"Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors","volume":"29","author":"Modali","year":"2015","journal-title":"Mol Endocrinol"},{"issue":"22","key":"2025092606115613600_bvaf147-B31","doi-asserted-by":"crossref","first-page":"e00278-17","DOI":"10.1128\/MCB.00278-17","article-title":"Long noncoding RNA MEG3 is an epigenetic determinant of oncogenic signaling in functional pancreatic neuroendocrine tumor cells","volume":"37","author":"Iyer","year":"2017","journal-title":"Mol Cell Biol"},{"issue":"6021","key":"2025092606115613600_bvaf147-B32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"issue":"7643","key":"2025092606115613600_bvaf147-B33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"2025092606115613600_bvaf147-B34","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"2025092606115613600_bvaf147-B35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"1","key":"2025092606115613600_bvaf147-B36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"6","key":"2025092606115613600_bvaf147-B37","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2025092606115613600_bvaf147-B38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"2025092606115613600_bvaf147-B39","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/healthcare10081569","article-title":"Neuroendocrine tumors: an analysis of prevalence, incidence, and survival in a hospital-based study in Ecuador","volume":"10","author":"Escobar","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"9","key":"2025092606115613600_bvaf147-B40","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025092606115613600_bvaf147-B41","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"issue":"12","key":"2025092606115613600_bvaf147-B42","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1245\/s10434-022-12350-1","article-title":"Long-term outcomes for patients with multiple endocrine neoplasia type 1 and duodenopancreatic neuroendocrine neoplasms","volume":"29","author":"Liu","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2025092606115613600_bvaf147-B43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000511791","article-title":"Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome\u2014an international consensus statement","volume":"111","author":"Niederle","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"7","key":"2025092606115613600_bvaf147-B44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2025092606115613600_bvaf147-B45","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cen.12411","article-title":"Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours","volume":"80","author":"Ramundo","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025092606115613600_bvaf147-B46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.11138\/ccmbm\/2017.14.1.123","article-title":"The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome","volume":"14","author":"Cioppi","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"10","key":"2025092606115613600_bvaf147-B47","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2154::AID-CNCR39>3.0.CO;2-W","article-title":"Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis","volume":"86","author":"Burgess","year":"1999","journal-title":"Cancer"},{"issue":"32","key":"2025092606115613600_bvaf147-B48","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025092606115613600_bvaf147-B49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1046\/j.1365-2362.1998.00397.x","article-title":"Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours","volume":"28","author":"Wulbrand","year":"1998","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"2025092606115613600_bvaf147-B50","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/SLA.0000000000003162","article-title":"Metastatic potential and survival of duodenal and pancreatic tumors in multiple endocrine neoplasia type 1: a GTE and AFCE cohort study (Groupe d'etude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne)","volume":"272","author":"Vinault","year":"2020","journal-title":"Ann Surg"},{"issue":"2","key":"2025092606115613600_bvaf147-B51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0016-5085(99)70124-1","article-title":"Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE)","volume":"116","author":"Cadiot","year":"1999","journal-title":"Gastroenterology"},{"issue":"11","key":"2025092606115613600_bvaf147-B52","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1210\/jcem.86.11.8011","article-title":"Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form","volume":"86","author":"Gibril","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025092606115613600_bvaf147-B53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00000658-200110000-00009","article-title":"Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome","volume":"234","author":"Norton","year":"2001","journal-title":"Ann Surg"},{"issue":"4","key":"2025092606115613600_bvaf147-B54","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jamcollsurg.2007.06.320","article-title":"Role of surgery in Zollinger-Ellison syndrome","volume":"205","author":"Norton","year":"2007","journal-title":"J Am Coll Surg"},{"issue":"2","key":"2025092606115613600_bvaf147-B55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/SLA.0b013e3182536339","article-title":"Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1","volume":"257","author":"Lopez","year":"2013","journal-title":"Ann Surg"},{"issue":"1","key":"2025092606115613600_bvaf147-B56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.sla.0000218073.77254.62","article-title":"Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias","volume":"244","author":"Tonelli","year":"2006","journal-title":"Ann Surg"},{"issue":"9","key":"2025092606115613600_bvaf147-B57","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199908263410902","article-title":"Surgery to cure the Zollinger-Ellison syndrome","volume":"341","author":"Norton","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"2025092606115613600_bvaf147-B58","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3748\/wjg.v17.i10.1343","article-title":"Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients","volume":"17","author":"Imamura","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"10","key":"2025092606115613600_bvaf147-B59","doi-asserted-by":"crossref","first-page":"bvac122","DOI":"10.1210\/jendso\/bvac122","article-title":"Metastatic grade 3 neuroendocrine tumor in multiple endocrine neoplasia type 1 expressing somatostatin receptors","volume":"6","author":"Graf","year":"2022","journal-title":"J Endocr Soc"},{"key":"2025092606115613600_bvaf147-B60","first-page":"19-0040","article-title":"Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1","volume":"2019","author":"Jhawar","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf147\/64225534\/bvaf147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/10\/bvaf147\/64225534\/bvaf147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/10\/bvaf147\/64225534\/bvaf147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:12:10Z","timestamp":1758881530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf147\/8249684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,5]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf147","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,5]]},"article-number":"bvaf147"}}